NCT00570310View on ClinicalTrials.gov

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Neuralgia, PostherpeticDiabetic NeuropathyPainful Small-Fiber NeuropathyIdiopathic Distal Sensory Polyneuropathy
Interventions
DRUG

Comparator: pregabalin

pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

DRUG

Comparator: Placebo (unspecified)

pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00570310 - Neuropathic Pain Syndrome Patient Study (MK-0000-072) | Biotech Hunter | Biotech Hunter